SCHEMBL21777424

SCHEMBL21777424

C=C(C)C(Cc1c(F)cccc1Br)C(=O)OCC

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.41
ALDH1A1 P00352 5/20 0.40
KDM4E B2RXH2 3/20 0.40
MMP8 P22894 1/20 0.39
MEN1 O00255 1/20 0.39
ATM Q13315 1/20 0.39
TDP1 Q9NUW8 4/20 0.36
ALOX15 P16050 1/20 0.36
NLRP3 Q96P20 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.35
TSHR P16473 3/20 0.35
POLB P06746 2/20 0.35
PIN1 Q13526 1/20 0.35
MAPK1 P28482 2/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
TP53 P04637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21787513 1.00 KMT2A (0.41) KMT2AALDH1A1KDM4EMMP8MEN1
SCHEMBL21787276 0.81 KMT2A (0.44) KMT2AALDH1A1KDM4EMMP8MEN1
SCHEMBL5736978 0.80 KMT2A (0.50) KMT2AALDH1A1KDM4EMMP8MEN1
SCHEMBL4035939 0.80 MMP8 (0.49) KMT2AALDH1A1MMP8MEN1TDP1
SCHEMBL14147393 0.78 MMP8 (0.50) KMT2AALDH1A1MMP8MEN1TDP1
SCHEMBL5737042 0.78 KMT2A (0.48) KMT2AALDH1A1KDM4EMMP8MEN1
SCHEMBL3714554 0.74 KMT2A (0.45) KMT2AALDH1A1KDM4EMMP8MEN1
SCHEMBL9956609 0.74 KMT2A (0.45) KMT2AALDH1A1KDM4EMMP8MEN1
SCHEMBL1246314 0.74 KMT2A (0.63) KMT2AALDH1A1KDM4EMEN1ATM
SCHEMBL11526043 0.74 MMP8 (0.41) KMT2AALDH1A1KDM4EMMP8MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3843728-B1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN MORPHIC THERAPEUTIC INC (US) 2025-04-30 EP disclosed
US-20230219949-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN MORPHIC THERAPEUTIC, INC. 2023-07-13 US disclosed
US-20230219949-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN MORPHIC THERAPEUTIC, INC. 2023-07-13 US disclosed
US-20230219949-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN MORPHIC THERAPEUTIC, INC. 2023-07-13 US disclosed
EP-3843728-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN Morphic Therapeutic, Inc. (US) 2021-07-07 EP disclosed
WO-2020047207-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN MORPHIC THERAPEUTICS, INC. (US) 2020-03-05 WO disclosed
WO-2020047207-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN MORPHIC THERAPEUTICS, INC. (US) 2020-03-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219949-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN ITGB6, ITGA6, ITGAV KMT2A 3926/4885ALDH1A1 1534/4885KDM4E 3514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.